Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...

Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trialSexual...

Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023 COLUMBUS, Ohio, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...

New FLORASSIST® Probiotic Women’s Health Supports Vaginal, Digestive and Immune Health Fort Lauderdale, FL, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Women’s probiotics designed to promote a healthy vaginal pH balance are increasingly popular in today’s supplement marketplace—but most...

Keeping Your Vagina Clean, Comfortable, and Happy, with the Newly Designed Patented Smooth Applicator TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Not everyone has symptoms when they’ve contracted vaginal infections, roughly 1 in 3 women contract bacterial vaginosis but many are unaware they have it....